{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:35:19Z","timestamp":1780104919523,"version":"3.54.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ad.2025.104491","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:27:16Z","timestamp":1764808036000},"page":"104491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real World Evidence of Secukinumab and Bimekizumab in Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8432-0954","authenticated-orcid":false,"given":"S.","family":"Haselgruber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Mu\u00f1oz-Barba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Soto-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cuenca-Barrales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4186-1435","authenticated-orcid":false,"given":"S.","family":"Arias-Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Molina-Leyva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2025.104491_bib0210","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.3390\/pharmaceutics15102450","article-title":"IL-17 inhibition: a valid therapeutic strategy in the management of hidradenitis suppurativa","volume":"15","author":"Malvaso","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ad.2025.104491_bib0215","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/bjd\/ljad345","article-title":"Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape","volume":"190","author":"Krueger","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.104491_bib0220","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2025.104491_bib0225","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials","volume":"403","author":"Kimball","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2025.104491_bib0230","unstructured":"Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients | ClinicalTrials.gov [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02421172 Cited 20.8.24."},{"key":"10.1016\/j.ad.2025.104491_bib0235","unstructured":"Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate-to-severe Hidradenitis Suppurativa | ClinicalTrials.gov [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05322473 Cited 20.8.24."},{"key":"10.1016\/j.ad.2025.104491_bib0240","unstructured":"Hidradenitis Suppurativa Phase 2b Pivotal Study of Izokibep | ClinicalTrials.gov [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05355805 Cited 20.8.24."},{"key":"10.1016\/j.ad.2025.104491_bib0245","unstructured":"Hidradenitis Suppurativa Study of Izokibep | ClinicalTrials.gov [Internet]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05905783 Cited 20.8.24."},{"key":"10.1016\/j.ad.2025.104491_bib0250","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4103\/picr.PICR_36_18","article-title":"Real world evidence (RWE) \u2013 are we (RWE) ready?","volume":"9","author":"Suvarna","year":"2018","journal-title":"Perspect Clin Res"},{"key":"10.1016\/j.ad.2025.104491_bib0255","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.3346\/jkms.2018.33.e213","article-title":"Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records","volume":"33","author":"Kim","year":"2018","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.ad.2025.104491_bib0260","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/ced\/llad229","article-title":"Bimekizumab in hidradenitis suppurativa: a valid and effective emerging treatment","volume":"48","author":"Molinelli","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ad.2025.104491_bib0265","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/bjd.15769","article-title":"Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report","volume":"179","author":"Thorlacius","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.104491_bib0270","article-title":"Therapeutic response to secukinumab in a 36-year-old woman with hidradenitis suppurativa","volume":"2018","author":"J\u00f8rgensen","year":"2018","journal-title":"Case Rep Dermatol Med"},{"key":"10.1016\/j.ad.2025.104491_bib0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLOS Med"},{"key":"10.1016\/j.ad.2025.104491_bib0280","unstructured":"OCEBM Levels of Evidence Working Group. \u201cThe Oxford Levels of Evidence 2\u201d. Oxford Centre for Evidence-Based Medicine. Available from: https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence."},{"key":"10.1016\/j.ad.2025.104491_bib0285","unstructured":"Study Quality Assessment Tools | NHLBI, NIH [Internet]. Available from: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools Cited 20.8.24."},{"key":"10.1016\/j.ad.2025.104491_bib0290","unstructured":"R Core Team. R: A language and environment for statistical computing [software]. Version 4.4.1. R Foundation for Statistical Computing; 2024. Available from: https:\/\/www.R-project.org\/."},{"key":"10.1016\/j.ad.2025.104491_bib0295","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/bjd.17822","article-title":"Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa","volume":"181","author":"Prussick","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.104491_bib0300","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jaad.2020.02.005","article-title":"Secukinumab in the treatment of moderate-to-severe hidradenitis suppurativa: results of an open-label trial","volume":"82","author":"Casseres","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.104491_bib0305","doi-asserted-by":"crossref","first-page":"e750","DOI":"10.1111\/jdv.16605","article-title":"Effectiveness of secukinumab in hidradenitis suppurativa: an open study (20 cases)","volume":"34","author":"Reguia\u00ef","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.104491_bib0310","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1111\/jdv.17178","article-title":"Effectiveness of secukinumab in the treatment of moderate\u2013severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting","volume":"35","author":"Ribero","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.104491_bib0315","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.1111\/jdv.18685","article-title":"Long-term secukinumab efficacy in patients with moderate-to-severe hidradenitis suppurativa: a retrospective single-centre case series (23 patients)","volume":"37","author":"Melgosa Ramos","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.104491_bib0320","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ad.2022.03.030","article-title":"Real-life experience of secukinumab in patients with hidradenitis suppurativa","volume":"114","author":"Melgosa Ramos","year":"2023","journal-title":"Actas Dermo-Sifiliogr"},{"key":"10.1016\/j.ad.2025.104491_bib0325","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s13555-023-00906-2","article-title":"Short-term effectiveness, safety, and potential predictors of response of secukinumab in patients with severe hidradenitis suppurativa refractory to biologic therapy: a multicenter observational retrospective study","volume":"13","author":"Fernandez-Crehuet","year":"2023","journal-title":"Dermatol Therapy"},{"key":"10.1016\/j.ad.2025.104491_bib0330","doi-asserted-by":"crossref","first-page":"adv5278","DOI":"10.2340\/actadv.v103.5278","article-title":"Drug survival of anti interleukin-17 and interleukin-23 agents after adalimumab failure in hidradenitis suppurativa: a pilot study","volume":"103","author":"Repetto","year":"2023","journal-title":"Acta Dermato-Venereol"},{"key":"10.1016\/j.ad.2025.104491_bib0335","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2147\/CCID.S449367","article-title":"Secukinumab in hidradenitis suppurativa patients who failed adalimumab: a 52-week real-life study","volume":"17","author":"Martora","year":"2024","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.ad.2025.104491_bib0340","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s13555-024-01209-w","article-title":"Insights into the window of opportunity and outcome measures in patients with moderate-to-severe hidradenitis suppurativa treated with secukinumab: a real-world study","volume":"14","author":"Haselgruber","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.ad.2025.104491_bib0345","doi-asserted-by":"crossref","DOI":"10.1111\/exd.15140","article-title":"Anti-IL17 Secukinumab in hidradenitis suppurativa: a long-term drug survival analysis","volume":"33","author":"Roccuzzo","year":"2024","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.ad.2025.104491_bib0350","doi-asserted-by":"crossref","first-page":"e823","DOI":"10.1111\/jdv.19921","article-title":"Eligibility in a cohort of patients with hidradenitis suppurativa treated with bimekizumab: lessons and pitfalls in a real-world setting","volume":"38","author":"Ure\u00f1a-Paniego","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.104491_bib0355","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1111\/ajd.14339","article-title":"Real-world effectiveness and safety of bimekizumab for hidradenitis suppurativa: an ambispective observational study","volume":"65","author":"Mansilla-Polo","year":"2024","journal-title":"Aust J Dermatol"},{"key":"10.1016\/j.ad.2025.104491_bib0360","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1016\/S0140-6736(24)00591-9","article-title":"Bimekizumab: dual inhibition as a promising tool in the management of hidradenitis suppurativa","volume":"403","author":"Molinelli","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2025.104491_bib0365","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/jdv.13216","article-title":"HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study","volume":"30","author":"Kimball","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.104491_bib0370","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/bjd.13270","article-title":"Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.104491_bib0375","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/jdv.18632","article-title":"Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa","volume":"37","author":"Tzellos","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.104491_bib0380","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1159\/000535867","article-title":"Viewpoint on the evaluation of severity and treatment effects in mild hidradenitis suppurativa: the cumulative IHS4","volume":"240","author":"van der Zee","year":"2024","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2025.104491_bib0385","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.104491_bib0390","first-page":"868","article-title":"S2k guideline for the treatment of hidradenitis suppurativa\/acne inversa \u2013 short version","volume":"22","author":"Zouboulis","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.ad.2025.104491_bib0395","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1071616","article-title":"Causal association between inflammatory bowel disease and hidradenitis suppurativa: a two-sample bidirectional Mendelian randomization study","volume":"14","author":"Bao","year":"2023","journal-title":"Front Immunol"},{"issue":"suppl 2","key":"10.1016\/j.ad.2025.104491_bib0400","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0001-7310(17)30003-0","article-title":"Epidemiology of hidradenitis suppurativa and inflammatory bowel disease: are these two disease associated?","volume":"107","author":"Salgado-Boquete","year":"2016","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2025.104491_bib0405","doi-asserted-by":"crossref","first-page":"1124628","DOI":"10.3389\/fphar.2023.1124628","article-title":"IL-17 inhibitor-associated inflammatory bowel disease: a study based on literature and database analysis","volume":"14","author":"Deng","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ad.2025.104491_bib0410","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/annrheumdis-2020-217927","article-title":"Paradoxical gastrointestinal effects of interleukin-17 blockers","volume":"79","author":"Fauny","year":"2020","journal-title":"Ann Rheum Dis"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025007604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025007604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T13:31:42Z","timestamp":1769261502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731025007604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0001731025007604"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2025.104491","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real World Evidence of Secukinumab and Bimekizumab in Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2025.104491","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"104491"}}